NRx Pharmaceuticals


Trevena

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) recently reported positive clinical data for TRV045, its selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator. The 3-part randomized, double-blind, placebo-controlled Phase 1 study …

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator Read More